Spinal glial and proinflammatory cytokine actions are strongly implicated in pathological pain. Spinal administration of the anti-inflammatory cytokine interleukin (IL)-10 abolishes pathological pain and suppresses proinflammatory IL-1b and tumor necrosis factor alpha (TNF-a). Drugs that bind the cannabinoid type-2 receptor (CB 2 R) expressed on spinal glia reduce mechanical hypersensitivity. To better understand the CB 2 R-related anti-inflammatory profile of key anatomical nociceptive regions, we assessed mechanical hypersensitivity and protein profiles following intrathecal application of the cannabilactone CB 2 R agonist, AM1710, in 2 animal models; unilateral sciatic nerve chronic constriction injury (CCI), and spinal application of human immunodeficiency virus-1 glycoprotein 120 (gp120), a model of peri-spinal immune activation. In CCI animals, lumbar dorsal spinal cord and corresponding dorsal root ganglia (DRG) were evaluated by immunohistochemistry for expression of IL-10, IL-1b, phosphorylated p38-mitogen-activated-kinase (p-p38MAPK), a pathway associated with proinflammatory cytokine production, glial cell markers, and degradative endocannabinoid enzymes, including monoacylglycerol lipase (MAGL). AM1710 reversed bilateral mechanical hypersensitivity. CCI revealed decreased IL-10 expression in dorsal spinal cord and DRG, while AM1710 resulted in increased IL-10, comparable to controls. Adjacent DRG and spinal sections revealed increased IL-1b, p-p38MAPK, glial markers, and/or MAGL expression, while AM1710 suppressed all but spinal p-p38MAPK and microglial activation. In spinal gp120 animals, AM1710 prevented bilateral mechanical hypersensitivity. For comparison to immunohistochemistry, IL-1b and TNF-a protein quantification from lumbar spinal and DRG homogenates was determined, and revealed increased DRG IL-1b protein levels from gp120, that was robustly prevented by AM1710 pretreatment. Cannabilactone CB 2 R agonists are emerging as anti-inflammatory agents with pain therapeutic implications. Ó
Introduction
Spinal sensitization of pain projection neurons is a critical process underlying pathological pain. Unilateral chronic constriction injury (CCI) of the sciatic nerve, as well as spinal inflammation following intrathecal (i.t.) human immunodeficiency virus (HIV)-1 glycoprotein-120 (gp120), is utilized here as animal models of pathological pain. While distinctly different in etiology, both models are characterized to involve activated spinal glia and proinflammatory cytokine activity [95] . Astrocytes and microglia produce interleukin (IL)-1b and tumor necrosis factor-alpha (TNF-a), which mediate pathological pain in a variety of animal models [14, 76] . Glia in spinal cord dorsal horn and dorsal root ganglia (DRG) [6, 33] show increases in phosphorylated p38 mitogen-activated kinase (pp38MAPK), a MAPK strongly associated with IL-1b and TNF-a expression [28] . DRG are home to glial satellite cells that generate IL-1b and TNF-a, additionally contributing to pathological pain in response to peripheral injury [23, 26, 63, 79, 80, 86, 87] . Conversely, IL-10 is a critical pleiotropic anti-inflammatory cytokine that suppresses IL-1b and TNF-a actions and blocks phosphorylation of factors that activate MAPK pathways, resulting in the inhibition of MAPK actions [22] . Lumbosacral i. transgene or protein leads to robust suppression of light touch hypersensitivity (allodynia) produced by CCI, as well as spinal inflammation following i.t. gp120 [55] [56] [57] .
Two cannabinoid receptor subtypes, CB 1 R and CB 2 R, are characterized to produce analgesic effects [85] . CB 1 Rs are present on neurons throughout the central nervous system (CNS), and their activation within the brain corresponds to a variety of effects beyond pain control [21] . However, CB 2 Rs are primarily expressed on microglia [71] and peripheral immune cells, including macrophages [74] . Activation of CB 2 Rs lack the known CNS side effects produced by CB 1 R activation [8, 21, 71, 72, 102] . Following peripheral nerve injury, increased expression of CB 2 Rs, endocannabinoids, and related degradative enzymes occur in DRG and spinal cord [41, 58, 94] . Reports demonstrate that the effects of CB 2 R activation reduce pathological pain, with a corresponding decrease in activation markers for spinal cord astrocytes, microglia, and factors associated with proinflammatory pathways [70, 73, 89, 94] . Given that the newly characterized cannabilactone, AM1710, binds CB 2 R with greater affinity than CB 1 R (54-fold CB 2 R > CB 1 R) [34, 61] , and its antinociceptive action is selectively blocked by CB 2 R antagonists [68] , i.t. administration of AM1710 was examined here for its potential actions to reverse or prevent allodynia produced by CCI and i.t. gp120, respectively. While prior reports reveal that spinal CB 2 R activation controls pathological pain responses in neuropathic rats [66, 67, 70, 72, 102] , the underlying spinal immunoregulatory signals in parallel with endocannabinoid degradative enzymes remain unclear.
The aim of the present study was to determine alterations in IL-10 immunoreactivity with concurrent reduction in immunoreactivity of CNS glial activation markers, IL-1b, p-p38MAPK, and the widely characterized endocannabinoid degradative enzymes, monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) in the dorsal horn and DRG in behaviorally verified CCI neuropathic rats following i.t. application of AM1710 [34, 68] . Bilateral allodynia was examined, as prior reports have documented this change from normal sensory responses [55, 64, 65] . Following i.t. gp120, cytokine protein levels surrounding the injection site and DRG were quantified by enzyme-linked immunosorbent assay (ELISA) procedures.
Methods

Animals
A total of 76 pathogen-free adult male Sprague-Dawley rats (300-400 g; Harlan Labs, Madison, WI, USA) were used in all experiments. Rats were double-housed in a temperature-and lightcontrolled (12-hour light/dark; lights on at 6:00 am) environment, with standard rodent chow and water available ad libitum. All procedures adhered to the guidelines of the Committee for Research and Ethical Issues of the International Association for the Study of Pain and were approved by the Institutional Animal Care and Use Committee of the University of the New Mexico Health Sciences Center.
Drugs
The CB 2 R agonist, 3-1(1 0 ,1 0 -Dimethylheptyl)-1-hydroxy-9-methoxy-6H-benzo[c]-chromene-6-one (AM1710) [34, 61] was used in these experiments. AM1710 was generously gifted by A.M. and G.T. AM1710 was first dissolved in 100% ethanol and diluted in sterile water (Hospira Inc, Lake Forest, IL, USA) for a final concentration of 1 mg/mL containing 5% ethanol. The vehicle of AM1710 was sterile water containing 5% ethanol. Pilot studies determined the dose range of AM1710, with a 100-fold dose range tested (10 lg-.1 lg in 10 lL or equivolume vehicle). Immediately prior to intrathecal (i.t.) injections, frozen (À80°C) recombinant gp120 (product 1021-2; lot number 7A3I20; ImmunoDiagnostics, Bedford, MA, USA) was thawed, and diluted to 0.5 lg/lL with 0.1% rat serum albumin in sterile phosphate-buffered saline (PBS), pH 7.4 (Life Technologies, Gaithersburg, MD, USA). Three micrograms in 6 lL or equivolume vehicle was prepared on ice, as detailed in prior reports [24, 52, 54, 82] .
Behavioral assessment of allodynia
Baseline (BL) responses to light mechanical touch were assessed using the von Frey test after animals were habituated to the testing environment, as previously described [9, 52] . Briefly, rats were placed atop 2-mm-thick parallel bars, spaced 8 mm apart and habituated for approximately 45 minutes for 5 days. All behavioral testing was performed during the first half of the light cycle in a sound-, light-, and temperature-controlled room. The von Frey test utilizes a series of calibrated monofilaments (3.61-5.18 log stimulus intensity; North Coast Medical, Morgan Hills, CA, USA) applied randomly to the left and right plantar surface of the hind paw for 8 seconds. Lifting, licking, or shaking the paw was considered a response. For all behavioral testing, threshold assessment was performed in a blinded fashion by J.L.W.
Chronic constriction injury (CCI) surgery
Following BL behavioral assessment, the surgical procedure for chronic constriction of the sciatic nerve was completed as previously described [4] . Briefly, in isoflurane (induction 5% vol. followed by 2.5% in oxygen)-anesthetized rats, the mid to lower back and the dorsal left thigh were shaved and cleaned with diluted Bacti-Stat AE (EcoLab HealthCare Division, Mississauga, ON, Canada). Using aseptic procedures, the sciatic nerve was carefully isolated, and loosely ligated with 4 segments of chromic gut sutures (Ethicon, Somerville, NJ, USA). Sham surgery was identical to CCI surgery but without the nerve ligation. The overlying muscle was sutured closed with (2) 3-0 sterile silk sutures (Ethicon), and animals recovered from anesthesia within approximately 5 minutes. Animal placement into either CCI or sham surgical groups was randomly assigned.
Chronic indwelling catheter surgery used for i.t. gp120 administration
Following BL assessment for light mechanical touch, chronic indwelling i.t. catheterization was performed as previously described in experiments utilizing gp120 for the induction of allodynia [50, 52, 54] . All animals recovered from this procedure within 5 minutes without overt signs of motor weakness or discomfort. Verification of lumbar PE-10 catheter placement was conducted at the time of tissue collection. One hundred percent of catheters were successfully placed within the intrathecal L5 lumbar region.
Intrathecal injection for chronic indwelling catheters
For chronic indwelling catheters in gp120 experiments, all drugs were prefilled into an ''i.t. injection catheter'' as detailed previously [50] . A 3-minute i.t. injection was administered in alert, conscious rats with light towel restraint. No overt motor weakness was observed. Six microliters of gp120 followed by an 8-lL sterile saline flush during a 10-second interval was injected.
Acute intrathecal injection used in CCI-related experiments
In rats with CCI, all drugs were administered via acute i.t. catheter placement. Injections were performed as previously described [52] . Either 10-lL drug or equivolume vehicle was withdrawn into the injection catheter, which was gently inserted and threaded rostrally to the 7.7-cm marking to achieve a catheter-tip position at the i.t. lumbosacral enlargement ($L4-L5). During this time, light tail twitching and a small amount of cerebrospinal fluid efflux from the 18-gauge needle was typically observed, indicating successful i.t. catheter placement. Drug or vehicle was injected during a 10-second interval. Drug treatment was randomly assigned to animals. Upon completion of injection, the PE-10 i.t. catheter was removed, followed by removal of the 18-gauge needle. A 100% motor recovery rate was observed from this injection procedure.
Immunohistochemical procedures from CCI-treated rats
Following behavioral assessment, animals were overdosed with an intraperitoneal injection of sodium phenobarbital (Sleepaway, Fort Dodge Animal Health, Fort Dodge, IA, USA), then perfused transcardially with saline followed by 4% paraformaldehyde. Whole vertebral columns with intact spinal cords (cervical 2 through sacral 1 spinal column segments) were removed, and underwent overnight fixation in 4% paraformaldehyde at 4°C. This tissue collection approach ensured that all relevant anatomical components, including the spinal cord, DRG, and overlying meninges, were intact within the vertebral column, allowing important spatial relationships to remain for examining corresponding functional interactions at individual and specific spinal cord levels. All specimens underwent ethylenediaminetetraacetic acid (Sigma Aldrich, St. Louis, MO, USA) decalcification for 30 days, and spinal cord sections were subsequently paraffin processed and embedded in Paraplast Plus Embedding Media (McCormick Scientific, St. Louis, MO, USA) as previously described [93] . Adjacent tissue sections (7 lm) were mounted on Vectabond-treated slides (Vector Labs, Burlingame, CA, USA), and allowed to adhere to slides overnight at 40°C, followed by deparaffinization, and rehydration via descending alcohols to PBS (1Â, pH 7.4). Sections were then processed with microwave antigen retrieval procedures (citrate buffer pH 6.0, or tris-based buffer, pH 9.0; BioCare Medical, Concord, CA, USA).
Slides were incubated with 5% normal donkey serum in PBS (pH 7.4) for 2 hours, followed by overnight primary antibody (Table 1) incubation in a humidity chamber at 3°C. Slides underwent secondary antibody incubation (Table 1) for 2 hours in a humidity chamber at room temperature, rinsed in PBS, and then coverslipped with Vectashield containing the nuclear stain 4 0 ,6-diamidino-2-phenylindole (DAPI) (Vector Labs). For detection of MAGL, phosphorylated p38MAPK, and IL-10 protein, sections were incubated overnight with primary antibodies, incubated with biotinylated secondary antibody (Table 1 ) for 1 hour, and then treated with Vectastain ABC Elite kit (Vector Labs) and stained using TSA Plus Fluorescein System (PerkinElmer Life Sciences, Waltham, MA, USA), and finally, coverslipped with Vectashield containing DAPI. Stained section orientation was kept consistent throughout for proper identification of ipsilateral and contralateral spinal cord and DRGs. For lumbar spinal cord, sections were taken from L4-L6, and the dorsal horn analyzed (Supplemental Fig. 1A ). The intact meninges overlying the ipsilateral dorsal horn of the spinal cord were analyzed separately to discern possible immunoreactive changes between surgical and drug treatment groups that may be different from quantified values obtained for the entire ipsilateral dorsal horn. For meningeal analysis, those sections revealing clear identification of the meninges vs. superficial spinal cord were chosen. As such, meninges of tissue sections comprising complete groups stained for IL-10, Iba-1, and MAGL were analyzed. For DRG material, sections were taken containing the DRG corresponding to L5 spinal cord segment, and the most distal portion of the DRG was analyzed (Supplemental Fig. 1B ). Low magnification photomicrographs were obtained (Supplemental Fig. 1A , B) using a Nikon Optiphot fluorescent microscope (Nikon Inc., Melville, NY, USA) equipped with a DP2-BSW camera (Olympus; Center Valley, PA, USA).
Confocal microscopy
All tissue processing, slicing, and procedures for immunohistochemistry were identical to that described above. However, in these studies, more than one primary antibody was used and examined under confocal microscopy. Therefore, after the first antibody staining procedure, the slides went through subsequent staining procedures. This took place over multiple days to account for the times needed for individual antibody incubation and staining. Confocal microscopy at 63Â magnification was then performed on a Zeiss AxioObserver inverted LSM510 META confocal microscope utilizing Zen 2009 software (Carl Zeiss, AG, Oberkochen, Germany). Final images were generated from collapsed z-stacks comprising 17 images taken 0.393 lm apart on the z axis.
Immunohistochemical spectral image analysis
All images of the spinal cord dorsal horn, overlying meninges, and DRGs were captured by a Zeiss Axioscope Microscope, at 20Â magnification, with a Nuance Spectral Camera (Cambridge Research & Instrumentation, Woburn, MA, USA). Utilizing the Nuance computer software, the fluorescent wavelength emission spectra range was initially determined for each fluorophore utilized in the detection of the primary antibody of interest (DAPI, 488 nm ± 10 nm; fluorescein isothiocyanate [FITC] , 575 nm ± 5 nm; Rhodamine Red, 600 nm ± 5 nm) by using a control slide with only a drop of the pure fluorophore. This was performed in the absence of a tissue specimen that may potentially obscure the measurement of the fluorophore's emission spectra. Two sets of additional control slides with tissue sections were prepared, one with only PBS without primary or secondary antibody treatment, and the other without primary but with secondary antibody treatment. These control slides were used to objectively eliminate low-intensity fluorescence and autofluorescence background ''noise'' from our measurements (Supplemental Fig. 1C ). Using the control slides, the Nuance software allows the user to set an acceptable threshold of low-level emission fluorescent intensity (as opposed to the software ''autothreshold'' option) within and outside the defined wavelength range of interest between tissue samples. Emission values that fall below this acceptable threshold of low-level emission, within and outside the defined wavelength range of interest, were eliminated from our measurements (Supplemental Fig. 1D ). The fluorescent intensity threshold for each protein marker was determined by the user finding the most appropriate threshold that captures the specific FITC or Rhodamine Red staining for each protein marker within a tissue (eg, dorsal horn spinal cord or DRG). Once the optimal level of fluorescent threshold was determined for a particular protein marker, this level was held consistent throughout all of the treatment groups for the image analysis within each protein marker of interest (Supplemental Fig. 1D ). These steps were followed by software conversion allowing fluorescent wavelength intensity for each fluorophore to be converted to a numerical value. Autofluorescence was defined as that emission outside the defined wavelength of interest (eg, DAPI, 488 nm ± 10 nm; FITC, 575 nm ± 5 nm; Rhodamine Red, 600 nm ± 5 nm), as well as low-level emission that fell below the acceptable threshold of low-level emission fluorescent intensity. These specific autofluorescent and low-level background emission values were subtracted from the image (Supplemental Fig. 1E, F) , yielding a numerical value of true fluorescent emission intensity for each fluorophore [44, 45] .
Primary antibody staining procedures remained consistent to minimize intensity variations of each fluorophore (FITC or Rhodamine Red) used to detect the different primary antibodies of interest. To ensure that fluorophore binding was not impeded through possible steric hindrance of other proximal fluorophores, sections were labeled for only one cellular marker of interest on a slide.
The user also determined the minimum number of connected pixels on the computer screen for image analysis, counted as a region of interest (ROI) defined in the Nuance software system, which resulted in a software image containing distinctive morphology (ie, of cellular bodies and processes, pattern of protein expression) that was virtually identical to the morphology observed through the microscope for each protein marker. The minimum number of connected pixels would therefore be set higher for a protein expressed abundantly by a cell (ie, glial fibrillary acidic protein [GFAP] ) in comparison to a protein expressed sparsely, leading to a punctuate pattern (eg, IL-1b). These conditions resulted in an ROI, and were held consistent for both the ipsilateral and contralateral tissues in every experimental condition and for each antibody stain. The total area of each ROI, as measured by mm 2 , is calculated and is factored into the overall measurement of fluorescent intensity per second of exposure. The average count of fluorescent emission intensity per second exposure, per mm 2 , is the analyzed value that we report here. That is, fluorescent intensity average count/second/mm 2 , which takes into account the density as well as the intensity of the fluorophore detected. A total of 4 sections per animal (n = 3) were randomly selected and analyzed in this manner. By applying this novel method of data acquisition and analysis, experimenter bias is eliminated, yielding greater consistency and objectivity to fluorescent quantification.
Protein quantification by ELISA
Twenty minutes after i.t. gp120 and subsequent behavioral verification, rats were given an overdose intraperitoneal injection (0.8-1.3 cc) of sodium phenobarbital (Sleepaway) and perfused transcardially with ice-cold saline followed by exposure of the lumbosacral enlargement by laminectomy. After verifying subdural intrathecal catheter placement and cerebral spinal fluid (CSF) collection, the dorsal portion of the lumbosacral spinal cord and the corresponding bilateral L4-L6 DRG were collected separately into tubes and flash frozen in liquid nitrogen. Tubes were then stored at À80°C until assay. ELISA procedures were performed for IL-1b and TNF-a according to manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
Experimental paradigms 2.12.1. Behavioral efficacy of i.t AM1710 following CCI
Behavioral assessment of BL thresholds was conducted prior to CCI or sham surgical manipulation. Hind paw threshold responses were assessed 3 and 10 days after surgery. Immediately following behavioral assessment, rats (n = 6/group) were given an i.t. injection of AM1710 or vehicle. Hind paw threshold responses were reassessed during the following 24 hours at discrete time points.
Immunohistochemical detection of spinal and DRG changes
In a separate group of rats (n = 3/group), identical BL threshold assessment and surgical procedures were followed, as just described. Intrathecal AM1710 was injected at the dose (10 lg) identified to produce maximal reversal from allodynia produced by CCI. At the time of maximal efficacy ($3 hours), rats were deeply anesthetized, followed by procedures for immunohistochemistry analysis of tissue sections. Thus, all tissue sections from the dorsal horn of the spinal cord and the corresponding intact DRG were analyzed from behaviorally verified rats from different experimental manipulations (sham vs. CCI + vehicle vs. AM1710).
Behavioral efficacy of i.t. AM1710 following i.t. gp120
A separate group of rats were behaviorally verified for BL thresholds followed by chronic i.t. catheterization. Threshold values were reassessed 6 days later. Immediately thereafter, rats received i.t. AM1710 or vehicle, and hind paw threshold responses were reassessed 3 hours later (at maximal AM1710 efficacy). At this time, i.t. gp120 was injected, followed by threshold assessment at 20 minutes (n = 6 rats/group), and immediately followed by anesthetic overdose and tissue collection for protein quantification.
Data analysis
Psychometric behavioral analysis was performed as previously described [52] to compute the log stiffness that would have resulted in the 50% paw withdrawal rate. Briefly, thresholds were estimated by fitting a Gaussian integral psychometric function to the observed withdrawal rates for each of the tested von Frey hairs, using a maximum-likelihood fitting method [90] . For behavioral statistical analysis to assess the presence of allodynia, a 1-way analysis of variance (ANOVA) was used at BL, and a 2-way repeated-measures ANOVA was used at 3 and 10 days after CCI/sham surgery in CCI-related experiments. To determine AM1710 drug efficacy following i.t. injection on Day 10, a 3-way repeated-measures ANOVA was applied at 0.5-, 1-, 2-, and 2.95-hour time points. For experiments utilizing i.t. gp120, a 1-way ANOVA was used at BL, and a 2-way repeated-measures ANOVA was used at 6 days after indwelling catheter surgery, and immediately prior to i.t. gp120. A 2-way repeated-measures ANOVA was applied to assess AM1710 efficacy 20 minutes after i.t. gp120. All other data analysis was performed using a 1-way ANOVA. A P-value of <0.05 was considered statistically significant. The computer program GraphPad Prism version 4.03 (GraphPad Software Inc., San Diego, CA, USA) was used in all statistical analyses. All data are expressed as mean ± SEM. For post hoc analysis, Bonferroni test was performed.
Results
Intrathecal injection of AM1710 dose-dependently reverses CCIinduced allodynia
The CB 2 R cannabilactone agonist, AM1710, reversed allodynia produced by CCI. Prior to surgical manipulation, all groups exhibited similar bilateral (ipsilateral and contralateral) BL behavioral thresholds (Fig. 1A, B) . Following CCI, clear bilateral allodynia developed by Day 3 and 10, compared to sham-operated rats. On Day 10, following i.t. AM1710 or vehicle injection in sham-operated rats, AM1710 did not alter normal sensory threshold responses to light touch, as well as throughout the entire time course. However, in rats with CCI, i.t. AM1710 produced reversal from allodynia, with maximal efficacy observed at 3 hours following the highest dose (10 lg) injected, whereas a 10-fold lower dose (1.0 lg) attenuated allodynia. The lowest dose examined (0.1 lg) did not significantly alter threshold responses, with allodynia remaining stable through the last time point tested (24 hours). All CCI-treated rats revealed full allodynia at 5 hours after i.t. AM1710 treatment.
Immunohistochemical analysis of spinal cord dorsal horn
Peak behavioral efficacy after i.t. AM1710 injection was again observed at $3 hours, compared to neuropathic vehicle-injected rats ( Fig. 2A, B) , which is in support of the behavioral dose-response characterization above (Fig. 1A, B) . Bilateral IL-10 immunoreactivity (IR) in the spinal cord dorsal horn is dramatically decreased in CCI-induced neuropathic rats, compared to shamtreated rats (Fig. 2C, D) . However, treatment with AM1710 rescued IL-10 IR bilaterally, similar to levels found in non-neuropathic controls. The intact meninges surrounding the ipsilateral spinal cord revealed a trend toward decreased IL-10 IR in CCI animals treated with vehicle, however, no changes between treatment groups were observed (Fig. 2C, inset) . Representative fluorescent images of either sham treated with i.t. vehicle (Fig. 2K) , CCI treated with i.t. vehicle (Fig. 2L) , or with AM1710 (Fig. 2M) corresponding to the quantitative image analysis data, are presented. Moreover, confocal microscope examination reveals IL-10 expression in astrocytes (Fig. 6C, F) within superficial (Lam I-II) and deeper dorsal horn laminae (Lam III-V), and microglia ( Fig. 6I ; Lam I-III). It is notable that when IL-10 returns to non-neuropathic basal levels, allodynia is correspondingly reversed.
For IL-1b IR analysis, compared to non-neuropathic sham-operated rats given i.t. AM1710 or equivolume vehicle, CCI-induced neuropathy produced a robust unilateral increase in IL-1b IR in i.t. vehicle-injected animals (Fig. 2E, F) . Conversely, i.t. administration of AM1710 completely suppressed increased dorsal horn IL-1b IR. Representative fluorescent images are of sham-treated rats with i.t. vehicle (Fig. 2N) , CCI-treated rats with i.t. vehicle (Fig. 2O) , or CCI treated-rats with AM1710 injection (Fig. 2P ) that correspond to data examined by microscopy analysis. Interestingly, in comparison to IL-10 IR in CCI animals, IL-1b IR observed in the contralateral dorsal spinal cord was not substantially elevated when compared to non-neuropathic control animals.
We also examined dorsal horn p-p38MAPK IR. Compared to sham-operated rats given i.t. AM1710 or equivolume vehicle, CCI-induced neuropathy produced a robust bilateral increase in the dorsal horn of p-p38MAPK IR (Fig. 2G, H) . Unexpectedly, AM1710 did not alter ipsilateral or contralateral increases in pp38MAPK IR. Again, representative fluorescent images are presented, which correspond to image analysis of either sham-treated rats with i.t. vehicle (Fig. 2Q) , CCI-treated rats with i.t. vehicle (Fig. 2R) , or CCI-treated rats with AM1710 (Fig. 2S) .
Upon close examination of the nuclear specific dye, DAPI, no differences in fluorescence intensity as a consequence of either CCI procedures or i.t. drug injections were observed, suggesting that local lumbar cellular numbers remained relatively unchanged (Fig. 2I, J) .
While non-neuropathic sham-operated animals given i.t. AM1710 or equivolume vehicle exhibited similar Iba-1 IR levels, a marker for altered microglial activity, AM1710 did not modify the increased dorsal horn Iba-1 IR in CCI-treated rats during AM1710-induced reversal from allodynia, compared to CCI-treated treated rats with ongoing allodynia (Fig. 3A, B) . Therefore, despite robust suppression of dorsal horn IL-1b expression and full reversal of allodynia, local administration of AM1710 does not inhibit increased levels of spinal Iba-1 IR. Meningeal Iba-1 IR was significantly elevated in CCI-treated compared to non-neuropathic sham-treated rats (Fig. 3A, inset) . While a trend toward decreased Iba-1 IR was observed in meninges of CCI-treated rats given i.t. AM1710, this decrease was insignificant.
Bilateral dorsal horn GFAP IR expression in adjacent Iba-1 stained sections was examined. Compared to non-neuropathic sham-operated rats given i.t. AM1710 or equivolume vehicle, a robust bilateral increase in dorsal horn GFAP was demonstrated in neuropathic rats (Fig. 3C, D) . However, clear suppressive effects of AM1710 on astrocyte activation were observed. Intrathecal AM1710 strikingly reduced the bilateral increases in dorsal horn GFAP IR seen in CCI vehicle-treated rats (Fig. 3C, D) . Corresponding representative fluorescent images used for analysis are shown; sham-operated rats treated with either i.t. vehicle or AM1710 (Fig. 3E, F) , or CCI-treated rats injected with either i.t. AM1710 or equivolume vehicle (Fig. 3G, H) .
FAAH and MAGL IR were examined at maximal anti-allodynic efficacy of AM1710. Surprisingly, no changes were observed in FAAH IR between non-neuropathic sham and neuropathic CCI rats following i.t. AM1710 or equivolume vehicle (Fig. 4A, B) . However, the exact opposite was observed with MAGL IR. That is, neuropathic rats given i.t. vehicle showed a robust bilateral increase in dorsal horn MAGL IR compared to non-neuropathic sham-operated rats given i.t. AM1710 or equivolume vehicle (Fig. 4C, D) . These observed MAGL IR increases were robustly and ipsilaterally suppressed in spinal cords of rats treated with i.t. AM1710 (Fig. 4C , D). The intact meninges overlying the ipsilateral spinal cord were also separately analyzed. Different from dorsal spinal analysis, a significant increase in MAGL IR was observed from non-neuropathic sham rats given i.t. AM1710, compared to non-neuropathic rats given i.t. vehicle (Fig. 4C, inset) . Like dorsal spinal analysis, a clear increase in MAGL IR from CCI-treated rats given vehicle was measured. Representative corresponding fluorescent images of analyses from whole dorsal horn spinal cord are shown from sham-operated rats injected with either i.t. vehicle or AM1710 (Fig. 4E, F) , or CCI-treated rats with either i.t. vehicle or AM1710 (Fig. 4G, H) . While MAGL has been identified in neuronal and microglial cultures, we show that MAGL can be expressed in microglia in vivo (Fig. 6J, K, L) .
Immunohistochemical analysis of dorsal root ganglia
Non-neuropathic sham-operated rats given i.t. AM1710 or equivolume vehicle revealed low GFAP IR, a marker for satellite cells. In striking contrast, a robust bilateral increase in GFAP IR was observed in the DRG from CCI-induced neuropathic rats given i.t. vehicle (Fig. 5A, B) . However, AM1710 robustly blocked bilateral GFAP IR increases in DRG (Fig. 5A, B) . Ipsilateral, and not contralateral, DRG increases in levels of p-p38MAPK (Fig. 5C, D) and IL-1b (Fig. 5E, F) , and decreases in IL-10 ( Fig. 5G, H) were observed in vehicle-injected neuropathic rats. However, following i.t. AM1710, these immunoreactive changes in p-p38MAPK, IL-1b, and IL-10 significantly recovered to non-neuropathic controls levels. Representative corresponding p-p38MAPK and IL-10 immunofluorescent images of these analyses are shown from ipsilateral DRG of sham-operated rats treated with i.t. vehicle (Fig. 5I, L) , or CCI-treated rats given either i.t. vehicle (Fig. 5J, M) or AM1710 (Fig. 5K, N) . 
Identification of IL-10 expressed in dorsal horn astrocytes and microglia
Within the superficial laminae, IL-10 is not colabeled with GFAP-positive cells (Fig. 6A, B, C) . However, within the deeper laminae of the dorsal spinal cord, IL-10 is extensively colabeled with GFAP (Fig. 6D, E, F) , while colabeling with NF-H (neurons) was completely absent (data not shown). Additionally, Iba-1-positive cells (macrophages and/or resident microglia) express IL-10 protein in laminae I-III (Fig. 6G, H, I ). Pilot data determined the time course in which AM1710 blocked the ability of gp120 to induce allodynia. We found that 10 lg of AM1710 was sufficient in blocking the initial development of gp120-induced allodynia, with the antiallodynic effects gone by 60 minutes (data not shown). All animals revealed similar BL responses prior to i.t. lumbar cannula implantation, i.t. AM1710 or equivolume vehicle injection (Day 6), and immediately prior to i.t. gp120 (Fig. 7A, B) . As expected, a robust bilateral allodynia was observed in animals given i.t. pretreatment with the vehicle for AM1710 followed $3 hours later by i.t. gp120. In stark contrast, i.t. pretreatment with AM1710 completely prevented the initiation of the bilateral gp120-induced allodynia (Fig. 7A, B) . Tissue collected from these animals 20 minutes after gp120 administration revealed a robust increase in IL-1b protein levels and a strong trend toward increased TNF-a protein production in the L4-L6 DRG, corresponding to L4-L6 spinal segments exposed to i.t gp120, compared to controls (Fig. 7C, D) . However, IL-1b protein was significantly suppressed in animals given i.t. AM1710 pretreatment followed by gp120, while a strong trend toward blunted TNF-a protein production was measured. Expectedly, changes in IL1-b and TNF-a within either the CSF or the dorsal horn spinal cord was not observed at this early post-i.t. gp120 time point.
Discussion
In this study, we present evidence that a distinct antiinflammatory response is induced following spinal (i.t.) administration of the recently characterized cannabinoid CB 2 R agonist compound from the cannabilactone class, AM1710, which either prevents or reverses allodynia induced in 2 distinguishable animal models. The findings of each animal model will be discussed in turn. In the CCI model, a transitory bilateral reversal of allodynia from chronic unilateral CCI is observed following i.t. AM1710 administration. While AM1710 was previously shown to increase nociceptive thresholds following peripheral administration in naïve rats [34, 68] , this study reports that normal light touch sensory thresholds are not altered following i.t. AM1710 in nonneuropathic rats. Additionally, IR for IL-10 significantly decreased in CCI-treated rats. In striking contrast, i.t. AM1710 in CCI neuropathic animals reset bilateral IL-10 IR to basal levels. Overlying meninges revealed similar, albeit insignificant, trends in IL-10. Furthermore, using confocal microscopy, dorsal horn localization of IL-10 is observed in astrocytes and microglia in superficial and deeper laminae (III-V). Together, these findings suggest that spinal parenchyma IL-10 regulate glia to induce pain relief.
It is critical to note that in response to peripheral nerve injury, CNS cellular populations can increase by proliferation of microglia [85] , astrocytes [91] , or by influx of bone marrow-derived perivascular microglia and macrophages [100] . Thus, increased immunoreactivity of specific proteins in the lumbar spinal cord could simply be due to a general increase in cell numbers constitutively expressing these markers. However, DAPI IR of cellular nuclei remained constant in all experimental conditions, supporting the possibility that cellular-specific responses to CCI and AM1710 occurred.
Indeed, alterations in several proinflammatory markers were observed in the spinal cord dorsal horn following CCI. Bilateral increases in p-p38MAPK IR were observed, supporting prior work demonstrating that p-p38MAPK plays a critical role in mechanical allodynia that involves the action of proinflammatory cytokines, including IL-1b, in models of peripheral nerve lesions [28, 30, 62] . While increased ipsilateral spinal IL-1b mRNA was recently reported following sciatic nerve ligation [78] , the current data in this study are the first demonstration of increased unilateral IL-1b IR in anatomically intact spinal cord dorsal horn of rats with CCI-induced allodynia. As with IL-10, AM1710 reset IL-1b to basal levels, but p-p38MAPK remained completely unaltered by AM1710, suggesting that basal levels of IL-10 are not sufficient to suppress activated p-p38MAPK IR. In addition, the data reported here show that bilateral increases in GFAP IR were observed in neuropathic rats. Prior work suggests that increased GFAP expression may not simply be a cellular marker coincident with neuropathy, as has been frequently reported [18, 67, 77] , but rather, may play a critical role mediating neuropathic pain [35] . Interestingly, CB 2 R activation in neuropathic rats resulted in significantly reduced superficial dorsal horn GFAP IR [73] , which may occur via microglial alterations because astrocytes make contact with microglia. CB 2 R expression has been identified mostly in spinal microglia [8, 67, 70, 71, 102] . While AM1710 blunted increases in GFAP IR, Iba-1 IR remained unaltered. Iba-1 is one of several immunohistochemical markers used to identify active microglia [1, 32] . Spinal cord microglial activation, identified by Iba-1 immunohistochemistry staining, was reversed by 3 hours following treatment with a microglial-specific inhibitor [88] . Other markers include the CD11b/CD18 [54] , or translocator protein, formerly known as the peripheral benzodiazepine receptor [10] preferentially expressed in CNS macrophage/microglia. However, in contrast to prior reports revealing decreased microglial activation following i.t. CB 2 R activation [70, 73, 89] , we show that increased Iba-1 IR persists following i.t. AM1710 and during reversal from allodynia. However, interpretations of these results are limited, given that only a single microglial marker was used to examine microglial activation. Nevertheless, microglia produce the anti-inflammatory endocannabinoid 2-arachidonyl glycerol (2-AG) during pathological CNS conditions [83, 99] . Notably, microglia may also be a source of IL-10 [59] in the spinal cord. Indeed, colocalization of IL-10 in microglia within superficial and deeper spinal cord laminae (III-IV) in behaviorally reversed CCI-treated rats is shown in this report.
The bioavailability of endocannabinoids such as anandamide and 2-AG produced and released from neurons and microglia [83, 84, 94] are primarily controlled through enzymatic metabolism by FAAH and MAGL [3, 7, 47] . Inhibitors of FAAH and MAGL that result in increased CNS levels of anandamide and 2-AG suppress pathological pain [36, 37, 42, 46] . The current study uniquely shows increased dorsal horn MAGL IR of neuropathic rats that is reduced following i.t. AM1710 in allodynic-reversed rats. As noted above, microglia are a known source of 2-AG [83] , where the actions of MAGL have been described [60] . We additionally show that MAGL expression is colocalized in superficial dorsal horn microglia using confocal microscopy. Interestingly, no change in FAAH IR was observed.
Satellite glial cells in the DRG form a clear sheath around individual large and small sensory neurons, and when activated under neuropathic conditions, reveal enriched GFAP and IL-1b expression [6, 11, 35, 86, 87] . IL-1b released from satellite glia further stimulates sensory neurons. Notably, DRG p-p38MAPK expression is well characterized following peripheral nerve injury associated with pathological pain [29, 101] . Here, examination of DRG revealed increased unilateral p-p38MAPK, IL-1b, and bilateral perineuronal (satellite cells) GFAP IR in neuropathic animals, while i.t. AM1710 abolished all of these changes. Like that observed in spinal cord dorsal horn, DRG IL-10 expression was significantly diminished during chronic neuropathy, in support of prior reports [27, 35, 36, 75] , and AM1710 resulted in basal IL-10 IR levels.
Bilateral allodynia induced by unilateral sciatic nerve CCI is demonstrated in this study, supporting previous findings [5, 15, 43, 51, 55, 64, 65, 82] . Reports demonstrating bilateral biochemical changes in lumbar spinal cord substantiate these behavioral observations. Prior demonstrations include a decrease in a2-adrenergic receptor mRNA expression [40] , greater Fos protein in neurons [69] , and IL-6 mRNA upregulation [15] . However, unique findings from the present work reveal unilateral spinal cord dorsal horn IL-1b IR increases. Thus, the spinal actions of IL-1b must be critical for inducing ipsilateral biochemical changes that in turn alter contralateral spinal cord activity. One possible mechanism may involve ipsilateral IL-1bÀmediated astrocyte activation that spreads to the contralateral spinal cord via astrocyte gap-junctional communication. Evidence for a critical role of spinal gapjunctional communication leading to contralateral allodynia that is partly mediated by IL-1b has been reported in a model of localized sciatic nerve inflammation [82] .
Intrathecal HIV-1 gp120 is an informative model of pathological pain because the spinal actions of IL-1b, p-p38MAPK, and other proinflammatory factors are necessary for allodynia to develop [24, [52] [53] [54] . Here, the onset of gp120-induced allodynia replicated previously characterized allodynia [24, [52] [53] [54] 98] . However, an early time-point analysis of IL1-b reveals no changes in CSF or dorsal horn, in support of prior reports [53, 54] , while increases in DRG IL1-b are observed. Allodynia and increased protein levels of DRG IL-1b following i.t. HIV-1 gp120 were completely prevented by i.t. AM1710 pretreatment, supporting immunofluorescent quantitative IL-1b changes observed from DRG in CCI neuropathic animals.
CB 2 Rs can modulate various signal transduction pathways involved in controlling allodynia in the animal models utilized in this report; CCI and i.t. gp120. While each model initiates spinal glial responses with subsequent proinflammatory cytokine production by different pathways, their downstream intracellular pathways converge. In CCI, enhanced central terminal and dorsal horn neurotransmitter (glutamate, substance P), adenosine triphosphate and chemokine release occurs, activating their cognate receptors on surrounding microglia, astrocytes, and neurons [25, 31, 49, 76, 97] . Separately, i.t. gp120 activates microglia and astrocytes in their role as immunocompetent cells that release neuroactive substances culminating in allodynia [96] . However, for both models, activated MAPKs, such as extracellular signal-regulated kinases (ERK1/2), p38, and c-Jun N-terminal kinase (JNK), are critical contributors of glial intracellular signaling leading to IL-1b and TNF-a synthesis and pathological pain [24, 28, 38, 39, 48, 54] . Additionally, spinal nitric oxide (NO), highly reactive through secondary reactions creating reactive oxygen species, activates MAPKs [81] and mediates allodynia in both models [24, 48, 98] . CB 2 R activation impacts signaling pathways involving cAMP, ERK1/2, JNK, p38-MAPKs, and NO production [12, 13, 16, 17] by several potential mechanisms. First, CB 2 R activation induces the expression of MAPK phosphatase-1 in microglial cells, which acts to deactivate ERK1/2 and decrease NO production [16] . Second, CB 2 R activation induces IL-10 production [39] that is well established to suppress IL-1b, TNF-a, and NO production [59] . While CB 2 R-mediated IL-10 production requires p38, ERK1/2, and JNK-MAPK activation [13] , concurrent inhibition of downstream translocation to the nucleus of the transcription factor, nuclear factor kappa-B that triggers IL-1b and TNF-a transcriptional activation, occurs by disrupting cytoplasmic IkBa important for nuclear factor kappa-B translocation [12] . The recently recognized key glial receptor participating in pathological pain, toll-like receptor 4, may become activated not only by its classic ligand, lipopolysaccharide, but also by factors released from i.t. gp120-or CCI-activated glia and damaged neurons [92, 95] . An intriguing possibility is that CB 2 R activation may exert anti-inflammatory effects through the ceramide pathway [2] , as ceramide analogs and toll-like receptor 4 activation in microglia act synergistically to produce IL-10 via the p38MAPK pathway [19, 20] .
Together, the implication of these results is that CB 2 R compounds capable of acting on both the spinal cord and DRG glial cytokines can control clinically relevant pathological pain conditions.
